JP2019529553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529553A5 JP2019529553A5 JP2019536696A JP2019536696A JP2019529553A5 JP 2019529553 A5 JP2019529553 A5 JP 2019529553A5 JP 2019536696 A JP2019536696 A JP 2019536696A JP 2019536696 A JP2019536696 A JP 2019536696A JP 2019529553 A5 JP2019529553 A5 JP 2019529553A5
- Authority
- JP
- Japan
- Prior art keywords
- phosphono
- propionyl
- carbonyl
- methoxy
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000013078 crystal Substances 0.000 claims 4
- 239000012454 non-polar solvent Substances 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- 238000010586 diagram Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- PKIFIIJFQKTNCT-IUQUCOCYSA-N [(2R)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid hydrochloride Chemical compound Cl.CCCCOC(=O)N1CCN(CC1)C(=O)[C@H](CP(O)(O)=O)NC(=O)c1cc(nc(n1)-c1ccccc1)N1CC[C@@H](C1)OC PKIFIIJFQKTNCT-IUQUCOCYSA-N 0.000 claims 2
- VHYKUGOYPWERLD-UHFFFAOYSA-N butyl piperazine-1-carboxylate;hydrochloride Chemical compound Cl.CCCCOC(=O)N1CCNCC1 VHYKUGOYPWERLD-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000004569 Blindness Diseases 0.000 claims 1
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 1
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 1
- 150000001348 alkyl chlorides Chemical class 0.000 claims 1
- 206010001902 amaurosis Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000002178 crystalline material Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 235000013312 flour Nutrition 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016072562 | 2016-09-22 | ||
| EPPCT/EP2016/072562 | 2016-09-22 | ||
| PCT/EP2017/073858 WO2018055016A1 (en) | 2016-09-22 | 2017-09-21 | Crystalline forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529553A JP2019529553A (ja) | 2019-10-17 |
| JP2019529553A5 true JP2019529553A5 (enExample) | 2020-11-12 |
| JP7097369B2 JP7097369B2 (ja) | 2022-07-07 |
Family
ID=59923448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536696A Active JP7097369B2 (ja) | 2016-09-22 | 2017-09-21 | 結晶形 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10730896B2 (enExample) |
| EP (2) | EP3981774A1 (enExample) |
| JP (1) | JP7097369B2 (enExample) |
| KR (1) | KR102552795B1 (enExample) |
| CN (1) | CN109715639B (enExample) |
| AU (1) | AU2017331930B2 (enExample) |
| CA (1) | CA3037794A1 (enExample) |
| CL (1) | CL2019000728A1 (enExample) |
| CY (1) | CY1125052T1 (enExample) |
| DK (1) | DK3515924T3 (enExample) |
| EA (1) | EA201990723A1 (enExample) |
| ES (1) | ES2908572T3 (enExample) |
| HR (1) | HRP20220234T1 (enExample) |
| HU (1) | HUE057772T2 (enExample) |
| IL (1) | IL265445B2 (enExample) |
| LT (1) | LT3515924T (enExample) |
| MA (1) | MA46266B1 (enExample) |
| MX (1) | MX381590B (enExample) |
| MY (1) | MY193080A (enExample) |
| PH (1) | PH12019500567B1 (enExample) |
| PL (1) | PL3515924T3 (enExample) |
| PT (1) | PT3515924T (enExample) |
| RS (1) | RS62946B1 (enExample) |
| SI (1) | SI3515924T1 (enExample) |
| TW (1) | TWI752086B (enExample) |
| UA (1) | UA124073C2 (enExample) |
| WO (1) | WO2018055016A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE057772T2 (hu) | 2016-09-22 | 2022-06-28 | Idorsia Pharmaceuticals Ltd | Kristályos formák |
| US11179390B2 (en) | 2017-03-15 | 2021-11-23 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a P2Y12 receptor antagonist |
| DK4181872T3 (da) | 2020-07-15 | 2026-01-26 | Viatris Asia Pacific Pte Ltd | Vandig, farmaceutisk sammensætning omfattende en p2y12 receptorantagonist |
| MX2024000653A (es) * | 2021-07-13 | 2024-01-31 | Idorsia Pharmaceuticals Ltd | Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico. |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
| CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
| US6855715B1 (en) | 1999-06-14 | 2005-02-15 | Eli Lilly And Company | Serine protease inhibitors |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| CA2507657C (en) | 2002-12-11 | 2011-05-31 | Bayer Schering Pharma Aktiengesellschaft | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists |
| PT1611144E (pt) | 2003-04-09 | 2010-11-12 | Wyeth Llc | Derivados do ácido 2-(8,9-dioxo-2,6-diazabiciclo(5.2.0)- non-1(7)-eno-2-il)-alquil-fosfónico e sua utilização como antagonistas do receptor n-metil-d-aspartato (nmda) |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| ES2421448T3 (es) | 2005-10-21 | 2013-09-02 | Actelion Pharmaceuticals Ltd | Derivados de piperazina como agentes contra la malaria |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| CL2007003038A1 (es) | 2006-10-25 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| CA2684644A1 (en) | 2007-04-23 | 2008-10-30 | Sanofi-Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
| BRPI0819696B1 (pt) | 2007-11-29 | 2018-10-23 | Actelion Pharmaceuticals Ltd | compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto |
| JP5504171B2 (ja) | 2007-12-26 | 2014-05-28 | サノフイ | Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド |
| JP5560202B2 (ja) | 2007-12-26 | 2014-07-23 | サノフイ | Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体 |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| WO2010116328A2 (en) | 2009-04-08 | 2010-10-14 | Actelion Pharmaceuticals Ltd | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines |
| KR101728180B1 (ko) | 2009-04-22 | 2017-04-18 | 액테리온 파마슈티칼 리미티드 | 티아졸 유도체들 및 ｐ2ｙ12 수용체 길항제로서 이들의 용도 |
| HUE057772T2 (hu) | 2016-09-22 | 2022-06-28 | Idorsia Pharmaceuticals Ltd | Kristályos formák |
| US11179390B2 (en) | 2017-03-15 | 2021-11-23 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a P2Y12 receptor antagonist |
| DK4181872T3 (da) | 2020-07-15 | 2026-01-26 | Viatris Asia Pacific Pte Ltd | Vandig, farmaceutisk sammensætning omfattende en p2y12 receptorantagonist |
-
2017
- 2017-09-21 HU HUE17771436A patent/HUE057772T2/hu unknown
- 2017-09-21 ES ES17771436T patent/ES2908572T3/es active Active
- 2017-09-21 MX MX2019003093A patent/MX381590B/es unknown
- 2017-09-21 CA CA3037794A patent/CA3037794A1/en active Pending
- 2017-09-21 LT LTEPPCT/EP2017/073858T patent/LT3515924T/lt unknown
- 2017-09-21 EA EA201990723A patent/EA201990723A1/ru unknown
- 2017-09-21 PL PL17771436T patent/PL3515924T3/pl unknown
- 2017-09-21 MY MYPI2019001474A patent/MY193080A/en unknown
- 2017-09-21 MA MA46266A patent/MA46266B1/fr unknown
- 2017-09-21 JP JP2019536696A patent/JP7097369B2/ja active Active
- 2017-09-21 KR KR1020197011330A patent/KR102552795B1/ko active Active
- 2017-09-21 SI SI201731102T patent/SI3515924T1/sl unknown
- 2017-09-21 EP EP21206477.8A patent/EP3981774A1/en not_active Withdrawn
- 2017-09-21 WO PCT/EP2017/073858 patent/WO2018055016A1/en not_active Ceased
- 2017-09-21 TW TW106132387A patent/TWI752086B/zh active
- 2017-09-21 HR HRP20220234TT patent/HRP20220234T1/hr unknown
- 2017-09-21 CN CN201780057793.2A patent/CN109715639B/zh active Active
- 2017-09-21 PT PT177714367T patent/PT3515924T/pt unknown
- 2017-09-21 IL IL265445A patent/IL265445B2/en unknown
- 2017-09-21 PH PH1/2019/500567A patent/PH12019500567B1/en unknown
- 2017-09-21 UA UAA201903751A patent/UA124073C2/uk unknown
- 2017-09-21 AU AU2017331930A patent/AU2017331930B2/en active Active
- 2017-09-21 RS RS20220163A patent/RS62946B1/sr unknown
- 2017-09-21 US US16/335,973 patent/US10730896B2/en active Active
- 2017-09-21 EP EP17771436.7A patent/EP3515924B1/en active Active
- 2017-09-21 DK DK17771436.7T patent/DK3515924T3/da active
-
2019
- 2019-03-21 CL CL2019000728A patent/CL2019000728A1/es unknown
-
2020
- 2020-07-24 US US16/938,730 patent/US11365209B2/en active Active
-
2022
- 2022-03-09 CY CY20221100195T patent/CY1125052T1/el unknown
- 2022-05-10 US US17/741,427 patent/US12227532B2/en active Active
-
2025
- 2025-01-17 US US19/028,423 patent/US20250163086A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4138886B2 (ja) | ２−アミノ−４−（４−フルオルベンジルアミノ）−１−エトキシカルボニル−アミノベンゼンの新規変態ならびにその製造法 | |
| CN1056609C (zh) | 苯甲酰胍衍生物及其制备方法和在药物组合物中的应用 | |
| JP2014522388A5 (enExample) | ||
| TWI711626B (zh) | 達格列淨新穎特別晶型及其製備方法 | |
| JP2017504576A5 (enExample) | ||
| CA2412941A1 (en) | Piperidine compounds for use as ccr-3 inhibitors | |
| CN1382682A (zh) | 2－(α－羟基戊基)苯甲酸盐及其制法和用途 | |
| JP2018516883A5 (enExample) | ||
| WO2016107289A1 (zh) | 制备索非布韦晶型6的方法 | |
| HRP20251307T1 (hr) | Kristalni oblik trietilentetramin tetrahidroklorida i njegova farmaceutska upotreba | |
| JP2006151999A5 (enExample) | ||
| JP2017535510A5 (enExample) | ||
| CN106866483A (zh) | 布瓦西坦的晶型c及其制备方法 | |
| CN102311382A (zh) | 罗氟司特的新晶态及其制备方法 | |
| HRP20220234T1 (hr) | Kristalni oblici | |
| RU2007116037A (ru) | Новая кристаллическая форма (3-циано-1н-индол-7-ил)-[4-(4-фторфенэтил)пиперазин-1-ил]метанона, гидрохлорида | |
| CN103819379A (zh) | 维生素d3的胆甾烷醇共结晶及其制备方法和应用 | |
| JP2010540440A5 (enExample) | ||
| CN109721579A (zh) | 7,8-脱氢葡萄藤戊素衍生物、其制法和药物组合物与用途 | |
| CN1452613A (zh) | 无定形的托拉塞米变体 | |
| JPWO2002018322A1 (ja) | 安息香酸誘導体結晶の製造方法 | |
| CN103408400B (zh) | 一种肌醇晶体及其制备方法和用途 | |
| US20110275834A1 (en) | Polymorph of strontium ranelate and a process for its preparation | |
| JP2707012B2 (ja) | Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法 | |
| JP2016505036A5 (enExample) |